Journal: Archives of biochemistry and biophysics

Article Title: LncRNA UCA1 promotes pancreatic cancer cell migration by regulating mitochondrial dynamics via the MAPK pathway.

doi: 10.1016/j.abb.2023.109783

Figure Lengend Snippet: Fig. 1. UCA1 expression in human cancers and clinicopathological characteristics in pancreatic cancer. (A) UCA1 expression in different cancer types based on the TCGA database. (ACC: Adrenocortical carcinoma, BLCA: Bladder Urothelial Carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, CHOL: Cholangiocarcinoma, COAD: Colon adenocarcinoma, DLBC: Lymphoid Neoplasm Diffuse Large B-cell Lymphoma, ESCA: Esophageal carcinoma, GBM: Glioblastoma multiforme, HNSC: Head and Neck squamous cell carcinoma, KICH: Kidney Chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute Myeloid Leukemia, LGG: Brain Lower Grade Glioma, LIHC: Liver hepatocellular carcinoma, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, MESO: Mesothelioma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PCPG: Pheochromocytoma and Paraganglioma, PRAD: Prostate adenocarcinoma, READ: Rectum adenocarcinoma, SARC: Sarcoma, SKCM: Skin Cutaneous Melanoma, STAD: Stomach adenocarcinoma, TGCT: Testicular Germ Cell Tumors, THCA: Thyroid carci noma, THYM: Thymoma, UCEC: Uterine Corpus Endometrial Carcinoma, UCS: Uterine Carcinosarcoma, UVM: Uveal Melanoma) (B, C) The expression of UCA1 is abnormal in pancreatic cancer by volcano map and boxplot. (D–G) The relationship between UCA1 expression and clinical characteristics in TCGA pancreatic cancer dataset, including Pathologic stage and clinical outcomes events. (*P < 0.05, **P < 0.01, ***P < 0.001) OS, overall survival; PFI, progression-free Interval; DSS, disease-free survival.

Article Snippet: Pancreatic cancer cells were treated with 20 μM of MEK1 inhibitor PD98059 (MedChemExpress, HY12028) for 24 h before western blotting.

Techniques: Expressing

Journal: Archives of biochemistry and biophysics

Article Title: LncRNA UCA1 promotes pancreatic cancer cell migration by regulating mitochondrial dynamics via the MAPK pathway.

doi: 10.1016/j.abb.2023.109783

Figure Lengend Snippet: Fig. 2. Clinical prognostic analysis of UCA1 expression in pancreatic cancer. (A–C) OS survival curve, PFI survival curve and DSS survival curve of UCA1. (D) Distribution of risk score, survival status of UCA1. (E) The AUC time-dependent curve of UCA1. (F) ROC curve for 1-, 2- and3-year survival prediction of UCA1. (G, H) Prognostic Calibration analysis and Prognostic Nomogram analysis of UCA1.

Article Snippet: Pancreatic cancer cells were treated with 20 μM of MEK1 inhibitor PD98059 (MedChemExpress, HY12028) for 24 h before western blotting.

Techniques: Expressing

Journal: Archives of biochemistry and biophysics

Article Title: LncRNA UCA1 promotes pancreatic cancer cell migration by regulating mitochondrial dynamics via the MAPK pathway.

doi: 10.1016/j.abb.2023.109783

Figure Lengend Snippet: Fig. 3. Prognostic values of UCA1 expression of pancreatic cancer patients evaluated by the Kaplan-Meier method in different subgroups. (A–F) OS survival curves of T3, N1, stage II, age ≤65 years, female and no radiation therapy. (G–K) DSS survival curves of Stage IV & Stage I & Stage III, T3, N1, no radiation therapy and age ≤65 years. (L–Q) PFI survival curves of N1, T3, age ≤65 years, no radiation therapy, female, and Stage II.

Article Snippet: Pancreatic cancer cells were treated with 20 μM of MEK1 inhibitor PD98059 (MedChemExpress, HY12028) for 24 h before western blotting.

Techniques: Expressing

Journal: Archives of biochemistry and biophysics

Article Title: LncRNA UCA1 promotes pancreatic cancer cell migration by regulating mitochondrial dynamics via the MAPK pathway.

doi: 10.1016/j.abb.2023.109783

Figure Lengend Snippet: Fig. 4. Prognostic values of UCA1 expression in patients with pancreatic cancer. (A) Forest plot of univariate Cox regression analysis. (B) Forest plot of multivariate Cox regression analysis.

Article Snippet: Pancreatic cancer cells were treated with 20 μM of MEK1 inhibitor PD98059 (MedChemExpress, HY12028) for 24 h before western blotting.

Techniques: Expressing

Journal: Archives of biochemistry and biophysics

Article Title: LncRNA UCA1 promotes pancreatic cancer cell migration by regulating mitochondrial dynamics via the MAPK pathway.

doi: 10.1016/j.abb.2023.109783

Figure Lengend Snippet: Fig. 5. Related differentially expressed genes of UCA1 in pancreatic cancer. (A–C) The volcano plot, correlation chord diagram and top ten related differentially expressed genes of UCA1 from TCGA database. (D–F) GO, KEGG and GSEA enrichment analysis of the high and low UCA1 expression groups and coexpression genes in TCGA dataset.

Article Snippet: Pancreatic cancer cells were treated with 20 μM of MEK1 inhibitor PD98059 (MedChemExpress, HY12028) for 24 h before western blotting.

Techniques: Expressing

Journal: Archives of biochemistry and biophysics

Article Title: LncRNA UCA1 promotes pancreatic cancer cell migration by regulating mitochondrial dynamics via the MAPK pathway.

doi: 10.1016/j.abb.2023.109783

Figure Lengend Snippet: Fig. 6. UCA1 promoted migration of pancreatic cancer cells. (A) The relative expression levels of UCA1 in human immortalized pancreatic ductal epithelial cell line H6C7 (HPDE6-C7) and different pancreatic cell lines (PANC1, PaTu8988 and BxPC3) were measured by qRT-PCR. (B) qRT-PCR was used to examine UCA1 expression in PANC1 and PaTu8988 cells transfected with pCDH-UCA1 and pCDH-Vector plasmids. (C) The expression level of UCA1 was tested in sh-UCA1-PaTu8988 and sh-UCA1-BxPC3 cells. (D, E) Transwell assays were used to detect the migrated ability of BxPC-3 and PANC1 cells transfected with sh-NC and sh-UCA1. (F, G) Transwell assays were used to examine the migrated ability of PaTu8988 and PANC1 cells transfected with pCDH-Vector and pCDH-UCA1. (*P < 0.05, **P < 0.01, ***P < 0.001).

Article Snippet: Pancreatic cancer cells were treated with 20 μM of MEK1 inhibitor PD98059 (MedChemExpress, HY12028) for 24 h before western blotting.

Techniques: Migration, Expressing, Quantitative RT-PCR, Transfection, Plasmid Preparation

Journal: Archives of biochemistry and biophysics

Article Title: LncRNA UCA1 promotes pancreatic cancer cell migration by regulating mitochondrial dynamics via the MAPK pathway.

doi: 10.1016/j.abb.2023.109783

Figure Lengend Snippet: Fig. 7. UCA1 increased mitochondrial membrane potential in pancreatic cancer cells. (A–C) Flow cytometry was used to detected the mitochondrial membrane potential of PaTu8988 and BxPC3 cells transfected with sh-NC and sh-UCA1 plasmids. (D–F) Flow cytometry was used to detected the mitochondrial membrane potential of PaTu8988 and PANC1 cells transfected with pCDH-UCA1 and pCDH- Vector plasmids.

Article Snippet: Pancreatic cancer cells were treated with 20 μM of MEK1 inhibitor PD98059 (MedChemExpress, HY12028) for 24 h before western blotting.

Techniques: Membrane, Flow Cytometry, Transfection, Plasmid Preparation

Journal: Archives of biochemistry and biophysics

Article Title: LncRNA UCA1 promotes pancreatic cancer cell migration by regulating mitochondrial dynamics via the MAPK pathway.

doi: 10.1016/j.abb.2023.109783

Figure Lengend Snippet: Fig. 8. UCA1 enhanced mitochondrial fusion of pancreatic cancer cells. (A) Sh-UCA1-PaTu8988 and BxPC3 cells were stained with mitotracker, and images were captured by confocal laser scanning microscope (scale bar: 50 μm) (B) The expression of mitochondrial fusion and fission proteins was examined in sh-UCA1-PaTu8988 and BxPC3 cells by Western blot. (C) PCDH-UCA1-PaTu8988 and PANC1 cells were stained with mitotracker, and images were captured by confocal laser scanning microscope (scale bar: 50 μm) (D) The expression of mitochondrial fusion and fission proteins was examined in pCDH-UCA1-PaTu8988 and PANC1 cells by Western blot.

Article Snippet: Pancreatic cancer cells were treated with 20 μM of MEK1 inhibitor PD98059 (MedChemExpress, HY12028) for 24 h before western blotting.

Techniques: Staining, Laser-Scanning Microscopy, Expressing, Western Blot